Evidence map›Paper›PMID 36607428›Full record

ArticleJournal of cancer research and clinical oncology2023

Total marrow irradiation versus total body irradiation using intensity-modulated helical tomotherapy.

Mümtaz Köksal, Laura Kersting, Felix Schoroth, Stephan Garbe, David Koch, Davide Scafa, Gustavo R Sarria, Christina Leitzen, Annkristin Heine, Tobias Holderried and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Mümtaz KöksalDepartment of Radiation Oncology, University Hospital Bonn, Bonn, Germany. muemtaz.koeksal@ukbonn.de.
Laura KerstingDepartment of Radiation Oncology, University Hospital Bonn, Bonn, Germany.
Felix SchorothDepartment of Radiation Oncology, University Hospital Bonn, Bonn, Germany.
Stephan GarbeDepartment of Radiation Oncology, University Hospital Bonn, Bonn, Germany.
David KochDepartment of Radiation Oncology, University Hospital Bonn, Bonn, Germany.
Davide ScafaDepartment of Radiation Oncology, University Hospital Bonn, Bonn, Germany.
Gustavo R SarriaDepartment of Radiation Oncology, University Hospital Bonn, Bonn, Germany.
Christina LeitzenDepartment of Radiation Oncology, University Hospital Bonn, Bonn, Germany.
Annkristin HeineDepartment of Internal Medicine-Oncology/ Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany.
Tobias HolderriedDepartment of Internal Medicine-Oncology/ Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany.
Peter BrossartDepartment of Internal Medicine-Oncology/ Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany.
Eleni ZogaDeprtment of Radiation Oncology, Sana Hospital Offenbach, Offenbach, Germany.
Ulrike AttenbergerDepartment of Radiology, University Hospital Bonn, Bonn, Germany.
Leonard C SchmeelDepartment of Radiation Oncology, University Hospital Bonn, Bonn, Germany.
University Hospital Bonn · DESana Klinikum Offenbach · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTotal body irradiation (TBI) is often a component of the conditioning regimen prior to hematopoietic stem cell transplantation in patients with hematological malignancies. However, total marrow irradiation (TMI) could be an alternative method for reducing radiation therapy-associated toxicity, as it specifically targets the skeleton and thus could better protect organs at risk. Here, we compared dosimetric changes in irradiation received by the target volume and organs at risk between TBI and TMI plans. MATERIALS AND

methodsTheoretical TMI plans were calculated for 35 patients with various hematological malignancies who had already received TBI in our clinic. We then statistically compared irradiation doses between the new TMI plans and existing TBI plans. We examined whether TMI provides greater protection of organs at risk while maintaining the prescribed dose in the targeted skeletal area. We also compared beam-on times between TBI and TMI.

resultsTMI planning achieved significant reductions in the mean, minimum, and maximum irradiation doses in the lungs, kidneys, liver, spleen, and body (i.e., remaining tissue except organs and skeleton). In particular, the mean dose was reduced by 49% in the liver and spleen and by 55-59% in the kidneys. Moreover, TMI planning reduced the corpus beam-on time by an average of 217 s.

conclusionTMI planning achieved significant dose reduction in organs at risk while still achieving the prescribed dose in the target volume. Additionally, TMI planning reduced the beam-on time for corpus plans despite a high modulation factor.

Indexed as

Hematologic NeoplasmsRadiation InjuriesRadiotherapy, Intensity-ModulatedBone MarrowCarmustineEtoposideHumansRadiotherapy DosageRadiotherapy Planning, Computer-AssistedWhole-Body IrradiationCarmustineEtoposideHematological malignancyHematopoietic stem cell transplantationRadiotherapyTotal body irradiationTotal marrow irradiationTreatment planning

Identifiers

PMID36607428
PMCPMC10356893
OpenAlexW4313647755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.